{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:48:37Z","timestamp":1789886917526,"version":"4.0.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Research, Innlandet Hospital Trust, Norway","award":["150323"],"award-info":[{"award-number":["150323"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0169830","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T13:23:43Z","timestamp":1487769823000},"page":"e0169830","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis"],"prefix":"10.1371","volume":"12","author":[{"given":"Gia","family":"Deyab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hokstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Elling","family":"Whist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milada Cvancarova","family":"Sm\u00e5stuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torstein","family":"Lyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnbjorg","family":"Hjeltnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"MT Nurmohamed","year":"2015","journal-title":"Nature reviews Rheumatology"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S2453","article-title":"Cardiovascular co-morbidity in rheumatic diseases","volume":"4","author":"C Turesson","year":"2008","journal-title":"Vascular Health and Risk Management"},{"issue":"6917","key":"ref3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"P Libby","year":"2002","journal-title":"Nature"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"PM Ridker","year":"2003","journal-title":"Circulation"},{"key":"ref5","article-title":"Pentraxins and Collectins: Friend or Foe during Pathogen Invasion?","author":"SS Foo","year":"2015","journal-title":"Trends in microbiology"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.autrev.2010.08.001","article-title":"Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases","volume":"9","author":"F Atzeni","year":"2010","journal-title":"Autoimmunity Reviews"},{"key":"ref7","first-page":"471","article-title":"Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations","author":"K Yamasaki","year":"2009","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/acr.20094","article-title":"Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease","volume":"62","author":"I Hollan","year":"2010","journal-title":"Arthritis Care & Research"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/rheumatology\/keq005","article-title":"Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease","volume":"49","author":"UM Breland","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.20061301","article-title":"The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps","volume":"204","author":"S Jaillon","year":"2007","journal-title":"The Journal of experimental medicine"},{"key":"ref11","first-page":"10","article-title":"Pentraxin 3(PTX 3): An Endogenous Modulator of the Inflammatory Response","volume":"2012","author":"P. Kunes ZH","year":"2012","journal-title":"Mediators of Inflammation"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1365-2249.2000.01110.x","article-title":"Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)","volume":"119","author":"MM Luchetti","year":"2000","journal-title":"Clinical and Experimental Immunology"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/01.ATV.0000015595.95497.2F","article-title":"Production of the long pentraxin PTX3 in advanced atherosclerotic plaques","volume":"22","author":"MS Rolph","year":"2002","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-030409-101305","article-title":"An integrated view of humoral innate immunity: pentraxins as a paradigm","volume":"28","author":"B Bottazzi","year":"2010","journal-title":"Annual review of immunology"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2007.08.013","article-title":"Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure","volume":"155","author":"S Suzuki","year":"2008","journal-title":"American heart journal"},{"key":"ref16","article-title":"Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity","author":"G Okan","year":"2015","journal-title":"J Clin Lab Anal"},{"issue":"22","key":"ref17","first-page":"3453","article-title":"The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis","volume":"18","author":"S Uysal","year":"2014","journal-title":"European review for medical and pharmacological sciences"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"JMH Moll","year":"1973","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"S van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"S Pavy","year":"2006","journal-title":"Joint Bone Spine"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"MM Ward","year":"2016","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"D van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/03009742.2011.585350","article-title":"Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients","volume":"40","author":"G Hjeltnes","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1358863X12436708","article-title":"Reproducibility of different methods to measure the endothelial function","volume":"17","author":"S Onkelinx","year":"2012","journal-title":"Vascular medicine (London, England)"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"PO Bonetti","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"e31474","DOI":"10.1371\/journal.pone.0031474","article-title":"Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies","volume":"7","author":"M Knoflach","year":"2012","journal-title":"PloS one"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cyto.2016.04.009","article-title":"Levels of serum pentraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis","volume":"83","author":"I Tekeoglu","year":"2016","journal-title":"Cytokine"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6","article-title":"PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation","volume":"44","author":"F Fazzini","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.arcmed.2016.05.006","article-title":"Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis","volume":"47","author":"XL Huang","year":"2016","journal-title":"Archives of medical research"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrrheum.2012.56","article-title":"Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?","volume":"8","author":"PJ Mease","year":"2012","journal-title":"Nature reviews Rheumatology"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-155-7-201110040-00005","article-title":"Pentraxin-3 as a marker of disease activity in Takayasu arteritis","volume":"155","author":"L Dagna","year":"2011","journal-title":"Annals of internal medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"608414","DOI":"10.1155\/2014\/608414","article-title":"The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention","volume":"2014","author":"R Helseth","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"2","key":"ref34","first-page":"137","article-title":"Levels of pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis","volume":"39","author":"T Deniz","year":"2014","journal-title":"Acta reumatologica portuguesa"},{"issue":"3","key":"ref35","first-page":"415","article-title":"Long pentraxin 3: a marker of inflammation in untreated psoriatic patients","volume":"18","author":"V Bevelacqua","year":"2006","journal-title":"Int J Mol Med"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1177\/1535370213506435","article-title":"Serological markers in psoriatic arthritis: promising tools","volume":"238","author":"R Ramonda","year":"2013","journal-title":"Experimental biology and medicine (Maywood, NJ)"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","article-title":"Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study","volume":"81","author":"R Ramonda","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosis.2004.03.020","article-title":"Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells","volume":"175","author":"M Klouche","year":"2004","journal-title":"Atherosclerosis"},{"issue":"2\u20133","key":"ref39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12026-013-8417-8","article-title":"Pentraxin 3 is a marker of early joint inflammation in patients with juvenile idiopathic arthritis","volume":"56","author":"S Padeh","year":"2013","journal-title":"Immunologic research"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1479-5876-11-223","article-title":"Increased long-term expression of pentraxin 3 in irradiated human arteries and veins compared to internal controls from free tissue transfers","volume":"11","author":"T Christersdottir Bjorklund","year":"2013","journal-title":"J Transl Med"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"LC Silva","year":"2010","journal-title":"Immunotherapy"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"JA Wessels","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"M Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s13075-014-0479-z","article-title":"Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis","volume":"16","author":"E Tombetti","year":"2014","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.107.749234","article-title":"Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction","volume":"117","author":"M Salio","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"ref46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/CIRCULATIONAHA.108.806547","article-title":"Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis","volume":"120","author":"GD Norata","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"ref47","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","article-title":"Six persistent research misconceptions","volume":"29","author":"KJ Rothman","year":"2014","journal-title":"Journal of general internal medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0169830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:08:12Z","timestamp":1540019292000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169830"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169830","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]}}}